| |
| |
|
| Insider
Information: |
Spiegelman Daniel K |
| Relationship: |
Director |
| City: |
|
| State: |
|
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
5 |
|
| Direct
Shares |
148,092 |
|
|
Indirect Shares
|
6,673 |
|
|
| Direct
Value |
$4,955,193 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
154,765 |
|
|
| Total
Value |
$4,955,193 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
CV Therapeutics Inc |
CVTX |
SVP, CFO |
2009-04-09 |
67,489 |
2009-04-09 |
6,673 |
Premium* |
|
|
Cascadian Therapeutics, Inc |
CASC |
Director |
2018-03-09 |
0 |
2009-12-04 |
0 |
Premium* |
|
|
Biomarin Pharmaceutical Inc |
BMRN |
EVP, Chief Financial O... |
2019-04-30 |
47,686 |
2012-05-29 |
0 |
Premium* |
|
|
Relypsa Inc |
RLYP |
Director |
2016-09-01 |
0 |
2015-06-04 |
0 |
Premium* |
|
|
Myriad Genetics Inc |
MYGN |
Director |
2024-06-04 |
32,917 |
2020-05-27 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
182 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 3 of 8
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Financial Officer |
• – – |
2017-05-15 |
4 |
D |
$91.50 |
$157,563 |
D/D |
(1,722) |
25,104 |
0 |
- |
|
| CVTX |
CV Therapeutics Inc |
SVP, CFO |
• – – |
2006-12-05 |
4 |
D |
$12.84 |
$22,945 |
D/D |
(1,787) |
6,439 |
0 |
- |
|
| CVTX |
CV Therapeutics Inc |
SVP, CFO |
• – – |
2007-12-05 |
4 |
D |
$9.50 |
$16,977 |
D/D |
(1,787) |
17,233 |
0 |
- |
|
| CVTX |
CV Therapeutics Inc |
SVP, CFO |
• – – |
2007-12-11 |
4 |
D |
$9.40 |
$16,798 |
D/D |
(1,787) |
12,446 |
0 |
- |
|
| CVTX |
CV Therapeutics Inc |
SVP, CFO |
• – – |
2008-12-09 |
4 |
D |
$9.51 |
$16,994 |
D/D |
(1,787) |
15,301 |
0 |
- |
|
| CVTX |
CV Therapeutics Inc |
SVP, CFO |
• – – |
2008-12-11 |
4 |
D |
$8.48 |
$15,154 |
D/D |
(1,787) |
18,514 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Financial Officer |
• – – |
2015-06-04 |
4 |
D |
$120.46 |
$216,948 |
D/D |
(1,801) |
29,878 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Financial Officer |
• – – |
2016-06-03 |
4 |
D |
$90.00 |
$162,090 |
D/D |
(1,801) |
48,593 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Financial Officer |
• – – |
2017-06-02 |
4 |
D |
$90.72 |
$163,387 |
D/D |
(1,801) |
23,303 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Financial Officer |
• – – |
2017-03-16 |
4 |
AS |
$91.96 |
$182,908 |
D/D |
(1,989) |
14,471 |
0 |
- |
|
| CVTX |
CV Therapeutics Inc |
SVP, CFO |
• – – |
2008-12-12 |
5 |
GD |
$9.15 |
$18,300 |
D/D |
2,000 |
16,576 |
0 |
- |
|
| CVTX |
CV Therapeutics Inc |
SVP, CFO |
• – – |
2008-02-26 |
4 |
D |
$6.95 |
$13,928 |
D/D |
(2,004) |
9,953 |
0 |
- |
|
| CASC |
Cascadian Therapeutics, I... |
Director |
– • – |
2014-06-07 |
4 |
D |
$3.06 |
$6,255 |
D/D |
(2,044) |
36,827 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Financial Officer |
• – – |
2015-05-18 |
4 |
S |
$124.77 |
$256,905 |
D/D |
(2,059) |
75,585 |
0 |
- |
|
| CASC |
Cascadian Therapeutics, I... |
Director |
– • – |
2011-06-12 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,076 |
20,885 |
0 |
- |
|
| CASC |
Cascadian Therapeutics, I... |
Director |
– • – |
2017-06-12 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,148 |
12,969 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Financial Officer |
• – – |
2014-07-02 |
4 |
S |
$64.00 |
$142,656 |
D/D |
(2,229) |
70,905 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Financial Officer |
• – – |
2014-08-01 |
4 |
S |
$61.76 |
$137,652 |
D/D |
(2,229) |
68,676 |
0 |
- |
|
| RLYP |
Relypsa Inc |
Director |
– • – |
2015-06-04 |
4 |
A |
$0.00 |
$0 |
D/D |
2,250 |
2,250 |
0 |
- |
|
| RLYP |
Relypsa Inc |
Director |
– • – |
2016-06-21 |
4 |
A |
$0.00 |
$0 |
D/D |
2,250 |
3,487 |
0 |
- |
|
| RLYP |
Relypsa Inc |
Director |
– • – |
2016-09-01 |
4 |
D |
$32.00 |
$72,000 |
D/D |
(2,250) |
0 |
0 |
- |
|
| CASC |
Cascadian Therapeutics, I... |
Director |
– • – |
2017-06-24 |
4 |
D |
$3.78 |
$8,562 |
D/D |
(2,265) |
19,225 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Financial Officer |
• – – |
2017-03-03 |
4 |
D |
$93.95 |
$214,488 |
D/D |
(2,283) |
23,064 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Financial Officer |
• – – |
2017-03-06 |
4 |
AS |
$93.32 |
$214,916 |
D/D |
(2,303) |
20,761 |
0 |
- |
|
| CASC |
Cascadian Therapeutics, I... |
Director |
– • – |
2017-09-24 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,375 |
21,600 |
0 |
- |
|
182 Records found
|
|
Page 3 of 8 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
